Related Experiment Video
Updated: Jun 17, 2026
09:39
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
Published on: September 17, 2019
Antibody-drug conjugate targets.
1Genzyme Corporation, Framingham, MA 01701-9322, USA. Beverly.Teicher@Genzyme.com
Current Cancer Drug Targets
|December 23, 2009
Summary
Antibody-drug conjugates (ADCs) show promise for cancer treatment by targeting malignant cells. Despite past challenges, advancements in ADCs are paving the way for improved patient outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) leverage antibodies to deliver cytotoxic agents specifically to cancer cells.
- The development of ADCs has faced challenges including antibody source, drug potency, immunogenicity, toxicity, and linker stability.
Purpose of the Study:
- To review cell surface targets for ADCs, focusing on antibody-small molecule drug conjugates.
- To discuss the progress and potential of ADC technology in cancer therapy.
Main Methods:
- Review of literature on antibody-drug conjugate targets and development.
- Focus on cell surface proteins targeted by antibody-small molecule drug conjugates.
- Brief discussion of 34 investigated targets.
Main Results:
- Significant progress has been made in overcoming historical hurdles in ADC development.
- Numerous targets are under investigation, with nearly 20 ADCs in clinical trials.
- Only one ADC has received regulatory approval to date.
Conclusions:
- ADC technology has evolved considerably, addressing previous limitations.
- The field is advancing rapidly, with many ADCs progressing through clinical trials.
- ADCs hold significant potential to become a major therapeutic option for cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...